Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02680951 : Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
PhasePhase 1
AgesMin: 1 Year Max: 21 Years
Inclusion Criteria:

- Histologically confirmed relapsed or refractory Acute Myeloid Leukemia (AML) and meet
the following criteria: Relapsed disease is defined as AML in 1st or greater marrow
relapse; Refractory disease is defined as AML which failed to go into remission after
1st or greater relapse, OR AML which failed to go into remission after two or more
induction attempts from original diagnosis

- ? 5% blasts by morphology in the bone marrow or molecular evidence of at least 0.1%
leukemic blasts in the bone marrow

- Definitive evidence of t(8;21) or inv(16) by a CLIA approved cytogenetics laboratory
from initial diagnosis

- CNS or other sites of extramedullary disease. No cranial irradiation is allowed
during the protocol therapy

- Lansky ? 50 for patients ? 16 years old; Karnofsky ? 50 for patients > 16 years old

- Have fully recovered from the acute toxic effects of all prior chemotherapy,
immunotherapy, or radiation therapy prior to entering this study

- Have adequate renal and hepatic functions

- A shortening fraction greater than or equal to 27% by echocardiogram, OR ejection
fraction greater than or equal to 50% by radionuclide angiogram (MUGA)

- Must not have any evidence of dyspnea at rest, exercise intolerance, and must have a
pulse oximetry > 94% at sea level

- Patients with a seizure disorder may be enrolled if well controlled on
anticonvulsants at a dose that has been stable for at least 14 days

- Female participants of childbearing potential must have a negative urine or serum
pregnancy test confirmed within 24 hours prior to enrollment

- Female participants with infants must agree not to breastfeed their infants while on
this study

- Male and female participants of child-bearing potential must agree to use an
effective method of contraception approved by the investigator during the study and
for a minimum of 6 months after study treatment

Exclusion Criteria:

- Known allergy to any of the drugs used in the study

- Systemic fungal, bacterial, viral or other infection of which they exhibit ongoing
signs/symptoms related to the infection without improvement despite appropriate
antibiotics or other treatment

- Any clinically significant cardiovascular disease including: myocardial infarction or
ventricular tachyarrhythmia within 6 months, prolonged QTc > 480 msec by the
Fridericia correction, major conduction abnormality, such as 2nd or 3rd degree heart
block or symptomatic bundle branch block, unless a cardiac pacemaker is present

- Plans to administer non-protocol chemotherapy, radiation therapy, or immunotherapy
during the study period

- Refractory to red blood cell or platelet transfusions

- Receiving anti-coagulation therapy

- A need to administer drugs that inhibit platelet function, such as aspirin or

- Receiving any of the following potent CYP3A4 inducers or inhibitors: erythromycin,
clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St.
John's Wort

- Significant concurrent disease, illness, psychiatric disorder or social issue that
would compromise patient safety or compliance with the protocol treatment or
procedures, interfere with consent, study participation, follow up, or interpretation
of study results

- Individuals with Down syndrome and DNA fragility syndromes (such as Fanconi anemia,
Bloom syndrome)
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557